You just read:

Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 Receptor Modulator for Autoimmune Diseases

News provided by

Arena Pharmaceuticals, Inc.

Jul 29, 2015, 08:00 ET